FTX-6058 Shows Promise in Raising Fetal Hemoglobin in Healthy Adults

FTX-6058 Shows Promise in Raising Fetal Hemoglobin in Healthy Adults

305176

FTX-6058 Shows Promise in Raising Fetal Hemoglobin in Healthy Adults

FTX-6058, an investigational oral treatment being developed by Fulcrum Therapeutics for sickle cell disease (SCD) and beta-thalassemia, was found to be effective at raising the levels of fetal hemoglobin in healthy adults enrolled in a Phase 1 trial, according to new interim results. Study data also indicated that FTX-6058 was generally well-tolerated, with no serious adverse events reported to date. The Phase 1 trial (NCT04586985), underway at its single Altasciences Clinical Kansas site, is enrolling healthy adults, ages…

You must be logged in to read/download the full post.